CING Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

6.760

Open

6.270

VWAP

6.23

Vol

411.48K

Mkt Cap

69.89M

Low

5.920

Amount

2.56M

EV/EBITDA(TTM)

--

Total Shares

11.63M

EV

68.50M

EV/OCF(TTM)

--

P/S(TTM)

--

Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.

Show More

Events Timeline

(ET)

2026-03-20

07:50:00

Cingulate Files to Sell 3.5M Shares of Common Stock

2026-03-18 (ET)

2026-03-18

08:10:00

Cingulate CEO Announces Strengthened CTx-1301 Patent

2026-03-18

08:10:00

Cingulate's ADHD Drug CTx-1301 Receives Patent Allowance

2026-01-12 (ET)

2026-01-12

17:30:00

Cingulate Files $200M Mixed Securities Shelf

2025-11-13 (ET)

2025-11-13

08:11:32

Cingulate Announces Q3 Net Loss of $7.3 Million Compared to $4.1 Million Last Year

2025-11-10 (ET)

2025-11-10

08:23:13

Cingulate Appoints Downey as Chief Commercial Officer to Oversee CTx-1301 Launch Preparation

2025-10-28 (ET)

2025-10-28

08:21:28

Cingulate Reveals Phase 3 Results for CTx-1301, Achieves Primary Endpoint

News

seekingalpha

03-18seekingalpha

Cingulate Reports Slight Increase in Q4 Net Loss

stocktwits

03-16stocktwits

Cingulate's ADHD Drug Patent Approved by USPTO

NASDAQ.COM

01-23NASDAQ.COM

Biotech Stocks Surge: Coherus Up 9.09% in After-Hours Trading

Benzinga

2025-11-19Benzinga

Roth Capital Reaffirms Buy Rating on Cingulate, Reduces Price Target to $16

NASDAQ.COM

2025-10-24NASDAQ.COM

INBX Rises 81% Following Study Results; FEMY, CING, CYH Surge in After-Hours Trading

Newsfilter

2025-10-23Newsfilter

Cingulate's Top ADHD Candidate CTx-1301 Chosen for Podium Presentation at AACAP Annual Meeting

3 Analyst Rating

Wall Street analysts forecast CING stock price to rise

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

8.00

Averages

27.33

High

58.00

Current: 0.000

Low

8.00

Averages

27.33

High

58.00

Roth Capital

Buy

downgrade

$16 -> $14

AI Analysis

2026-03-22

Reason

Roth Capital

Price Target

$16 -> $14

AI Analysis

2026-03-22

downgrade

Buy

Reason

Roth Capital lowered the firm's price target on Cingulate to $14 from $16 and keeps a Buy rating on the shares. The company's new drug application for CTx-1301 in attention-deficit/hyperactivity disorder is awaiting FDA decision with a May 31 action date, the analyst tells investors in a research note. The firm updated Cingulate's model to reflect the Q4 results.

Roth Capital

Boobalan Pachaiyappan

Buy

downgrade

$17 -> $16

2025-11-18

Reason

Roth Capital

Boobalan Pachaiyappan

Price Target

$17 -> $16

2025-11-18

downgrade

Buy

Reason

Roth Capital analyst Boobalan Pachaiyappan lowered the firm's price target on Cingulate to $16 from $17 and keeps a Buy rating on the shares, with the firm noting it caught up with Cingulate management to discuss Q3 results. At a high level, the company is ratcheting up its CTx-1301 U.S. pre-commercialization efforts through its Indegene partnership, the analyst tells investors in a research note. The firm expects CTx-1301 approval by May 31, 2026.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CING

Unlock Now

Valuation Metrics

The current forward P/E ratio for Cingulate Inc (CING.O) is 0.00, compared to its 5-year average forward P/E of -8.50. For a more detailed relative valuation and DCF analysis to assess Cingulate Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-8.50

Current PE

0.00

Overvalued PE

51.96

Undervalued PE

-68.96

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

14.76

Current PS

9.43

Overvalued PS

56.79

Undervalued PS

-27.27

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

low float medical tech stock

Intellectia · 68 candidates

Market Cap: 50.00M - 5.00BSector: Healthcare, Healthcare Services & Equipment, Pharmaceuticals & Medical ResearchRegion: USPrice: $1.00 - $50.00Beta: ModerateRisk, HighRisk, LowRisk, NegativeBetaList Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 300,000Floating Shares: <= 20,000,000

Ticker

Name

Market Cap$

Xilio Therapeutics Inc

50.19M

Lipocine Inc

54.02M

LifeVantage Corp

54.88M

Clene Inc

63.49M

Outset Medical Inc

64.46M

Adicet Bio Inc

64.58M

what stocks are expected to rise today?

Intellectia · 87 candidates

Region: USPrice: $3.00 - $150.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20One Day Rise Prob: >= 60One Day Predict Return: >= 1.0%Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

Turbo Energy SA

38.23M

SIFCO Industries Inc

84.77M

Cable One Inc

583.89M

Spruce Biosciences Inc

86.15M

Intrepid Potash Inc

547.67M

Cingulate Inc

86.09M

best strong buy for today

Intellectia · 86 candidates

Analyst Consensus: Strong BuyList Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA20One Day Rise Prob: >= 55Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

Cingulate Inc

43.41M

Perspective Therapeutics Inc

261.77M

Enliven Therapeutics Inc

1.51B

ADTRAN Holdings Inc

757.90M

Universal Technical Institute Inc

1.52B

Centessa Pharmaceuticals PLC

3.82B

where do i go for sotck radar

Intellectia · 38 candidates

Price: $2.00 - $30.00Price Change Pct: >= $2.00Relative Vol: >= 1.50Beta: HighRisk

Ticker

Name

Market Cap$

Acumen Pharmaceuticals Inc

144.16M

Redwire Corp

2.39B

Ideal Power Inc

36.39M

KLX Energy Services Holdings Inc

49.23M

HUYA Inc

1.01B

Cingulate Inc

41.59M

Whales Holding CING

Trading Trends

People Also Watch

Frequently Asked Questions

What is Cingulate Inc (CING) stock price today?

The current price of CING is 6.01 USD — it has decreased -3.22

What is Cingulate Inc (CING)'s business?

Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.

What is the price predicton of CING Stock?

Wall Street analysts forecast CING stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CING is27.33 USD with a low forecast of 8.00 USD and a high forecast of 58.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Cingulate Inc (CING)'s revenue for the last quarter?

Cingulate Inc revenue for the last quarter amounts to -5.59M USD, decreased -10.02

What is Cingulate Inc (CING)'s earnings per share (EPS) for the last quarter?

Cingulate Inc. EPS for the last quarter amounts to -3753502.00 USD, decreased -12.26

How many employees does Cingulate Inc (CING). have?

Cingulate Inc (CING) has 14 emplpoyees as of April 02 2026.

What is Cingulate Inc (CING) market cap?

Today CING has the market capitalization of 69.89M USD.